Abstract
BackgroundThe efficacy and safety of upadacitinib (UPA), an oral JAK inhibitor, has been demonstrated in phase 3 trials for PsA, [1,2] AS, [3,4] and non-radiographic axial spondyloarthritis (nr-axSpA) [5].ObjectivesTo provide...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
